The company’s pipeline products include SLC-391 which targets non-small cell lung cancer, myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML); SLC-0111 treats pancreatic ductal ...

NEXI-001 is under clinical development by NexImmune and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase ...

Anthony Olson was diagnosed with Myelodysplastic syndromes (MDS) and went on to receive chemo for almost a decade to treat ...

Panelists discuss how the final efficacy and safety analysis from the COMMANDS trial (Della Porta et al, Lancet 2024) highlights the role of luspatercept in first-line treatment for lower-risk ...

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric ...

Did you know Robin Roberts’ openness about her health journey led to an astounding 1,800% increase in bone marrow donor ...

Anthony Olson was told he’d die without treatment and to ignore a negative biopsy. He’s one of many patients who may have ...

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic ...

A national survey of Canadian hematologists reveals gaps and variability in supportive care strategies for older adults with ...

Remedy Plan Therapeutics has commenced dosing in a randomised Phase I trial of hyperbolic nicotinamide ...

Keros Therapeutics is a clinical-stage biopharmaceutical company focusing on rare and hematological diseases. Read why I rate KROS stock a Hold now.